Aicaigou LogoAicaigou LogoB2B WikiIndustrial Encyclopedia

CA19-9 Antigen

Updated: 2026-07-17

Overview

CA19-9 (carbohydrate antigen 19-9) is a clinically important tumor marker first identified in 1981. While produced by normal pancreatic and biliary ductal cells, elevated levels are most commonly associated with pancreatic adenocarcinoma, where sensitivity reaches 70-90% in advanced cases. This glycoprotein antigen belongs to the Lewis blood group system and requires the presence of the Lewis antigen (Lea-b-) for expression. Approximately 5-10% of the population cannot produce CA19-9 due to genetic variations in fucosyltransferase enzymes.

Key Features

现货Phoenix/1830184连接器PTSM0,5/8-HTB-2,5-SMDWHR44原装正品深圳市八惠智发电子有限公司

The CA19-9 molecule is a sialylated lacto-N-fucopentaose II with molecular weight of approximately 36 kDa. Its expression correlates with tumor burden in pancreatic cancer, making it valuable for monitoring disease progression and treatment response. Important limitations include non-specific elevation in benign hepatobiliary conditions (cholestasis, cirrhosis) and other malignancies (colorectal, gastric, ovarian cancers). The marker demonstrates better specificity when combined with imaging findings and clinical presentation.

商家经验真实案例 · 安全可信
PIC16F526工作原理
本文深入浅出地解析PIC16F526微控制器的工作原理,包括其核心架构、指令执行流程以及典型应用场景,帮助读者快速掌握这款8位MCU的运作机制。

Application Areas

In clinical practice, CA19-9 serves three primary functions: aiding pancreatic cancer diagnosis when combined with imaging, monitoring treatment response during chemotherapy or radiation, and detecting early recurrence post-resection. Rising levels often precede radiographic evidence of progression by 1-6 months. The marker also finds use in distinguishing pancreatic cancer from chronic pancreatitis, though overlap exists. Emerging applications include predicting resectability and survival outcomes, with levels >1,000 U/mL typically indicating unresectable disease.

Precautions

强鼎国标亚硫酸氢钠 7631-90-5工业细菌抑制剂25kg山东强鼎化工有限公司

Clinical interpretation requires understanding several caveats: approximately 15% of pancreatic adenocarcinomas don't express CA19-9, benign biliary obstruction can cause marked elevation (often >1,000 U/mL), and levels vary by assay methodology. Providers should note that CA19-9 clearance differs from creatinine, with a half-life of approximately 4-14 days post-resection. False negatives may occur in Lewis antigen-negative patients, while false positives are common in smokers and patients with acute cholangitis.

商家经验真实案例 · 安全可信
pic16f688引脚定义
本文详细解析PIC16F688微控制器的引脚定义及其功能,帮助开发者快速理解各引脚的用途,为硬件设计提供参考。

B2B Procurement Guide

Healthcare institutions procuring CA19-9 testing services should evaluate analytical performance characteristics including limit of detection (typically 1-2 U/mL), measuring range (up to 10,000 U/mL), and reproducibility (<10% CV). Consider whether to purchase individual tests or include in tumor marker panels. Automated platforms (Roche Cobas, Abbott Architect) offer throughput advantages but require capital investment. For reference laboratories, verify accreditation (CAP, CLIA) and proficiency testing performance before contracting services.

Related Manufacturers